Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia

Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of droxidopa for the treatment of fibromyalgia. Top-line results of the trial are expected by the end of the year.

"We are delighted to have reached our target enrollment of this study slightly ahead of schedule," commented Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. "We are grateful to all the clinicians and patients who participated in this trial and we are eager to see the top-line results later this year."

An interim analysis conducted last year by an independent Data Monitoring Committee (DMC) showed meaningful efficacy in several of the study's treatment arms with no observed safety concerns associated with any arm of the study.